Please assess the completion status of the following clinical trial:

Trial Title: [S,S]-Reboxetine Add-On Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pain present for more than 3 months after the healing of shingles skin rash~* Patients at screening must have a score \>/=40 mm on the pain visual analogue scale~Exclusion Criteria:~* Patients with significant renal and hepatic impairment~* Patients with other severe pain, that may impair the self-assessment of the pain due to shingles~* Patients with clinically abnormal electrocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [S,S]-Reboxetine + Pregabalin (Type: EXPERIMENTAL): None
- Pregabalin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).